Belite Bio (BLTE) announced that United Kingdom’s, U.K., Medicines and Healthcare Products Regulatory Agency, MHRA, has agreed to accept a Conditional Marketing Authorization, CMA, application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial. MHRA’s response is based on the interim analysis results which fulfil the criteria for a Conditional Marketing Authorization application. The Company remains on track to report final topline data from the Phase 3 DRAGON trial in the fourth quarter of 2025. These results are expected to be submitted to the MHRA for full Marketing Authorization Application.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio price target raised to $132 from $80 at Benchmark
- Belite Bio management to meet virtually with Cantor
- Belite Bio files to sell 1.95M American Depositary Shares for holders
- Leerink bullish on Belite Bio, says tinlarebant news another positive data point
- Belite Bio announces China’s NMPA agreed to accept NDA for Tinlarebant